V116 shows safety and immunogenicity in high-risk children for pneumococcal disease
The phase 3 study demonstrated that V116 met noninferiority and superiority criteria for immunogenicity compared to PPSV23 in children with chronic conditions.
Asset / Drug
Drug and asset intelligence for PPSV23 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.